According to David Stefansky, Co-Founder of Kalytera and Chairman of the Board of Directors, “We are thrilled to announce the signing of this LOI, which brings us closer to acquiring a late-stage program in GvHD with strong proof-of-concept. There are currently few options to prevent or treat GvHD. We feel incredibly fortunate to be working towards the advancement of this important program.”
Andrew Salzman, M.D., Kalytera Chief Executive Officer added, “Multiple studies have demonstrated that CBD possesses remarkable therapeutic potential across a broad range of diseases and disorders. The proposed acquisition of Talent and its late-stage GvHD program significantly advances Kalytera’s mission of becoming a global leader in CBD pharmaceuticals. We are encouraged by Talent’s GvHD data, and we are hopeful that Kalytera will be able to rapidly advance the program into placebo-controlled, double-blind, randomized studies.”
Beyond their ground-breaking research, Kalytera has all the pieces in place to become a leader in the medical marijuana industry. They have assembled a leadership team composed of some of the greatest minds in medical research and development, including: David Stefansky, Co-Founder and Chairman, Andrew L. Salzman, MD., Chief Executive Officer and Chief Medical Officer, Raphael Mechoulam, Ph.D., Robert Farrell, President, COO and CFO, and Seth Yakatan, Co-founder and Director.
